ORIGIN = Outcome Reduction with Initial Glargine Intervention
A randomized study of patients with IFG and/or IGT or early T2DM and established CV disease or CV risk at baseline. Patients received either Lantus® (n=6264) titrated to a target FPG of ≤95 mg/dL or standard care (n=6273). Standard care patients remained on their original treatment, if applicable, at randomization. Additional agents could be added as needed per discretion of the investigator. Median follow-up: 6.2 years.1,2
No statistically significant differences between Lantus® and standard care in the co-primary endpoints. Similar results were observed between Lantus® and standard care for all-cause mortality.
From Lantus Prescribing Information.1
View Lantus® long-term CV safety data from the ORIGINS trial.
FPG = fasting plasma glucose; IFG = impaired fasting glucose; IGT = impaired glucose tolerance
See how Lantus® provides effective, improved glycemic control in diabetes patients.†
†Lantus® Prescribing Information. August 2015.
Lantus® is a once-daily, long-acting insulin.**
**Lantus® Prescribing Information. August 2015.
Lantus® is a basal insulin with demonstrated long-term CV safety data††